A Phase 3 interventional study of Silodosin and Placebo in Benign Prostatic Hyperplasia (BPH), sponsored by Watson Pharmaceuticals. Completed at 43 sites in United States. Open to male participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2011-07-12.
Sponsored by Watson Pharmaceuticals (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing silodosin in Prostatic Hyperplasia — 4 open to participants now, 4 under way, none of them phase 3. silodosin · Prostatic Hyperplasia.
Among the 19 studies testing silodosin in Prostatic Hyperplasia, this one is the 5th largest by enrollment, is one of 3 that started in 2005, is one of 4 in phase 3, and was the 1st registered.
828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.
Browse Prostatic Hyperplasia studies →4 of the 19 studies testing silodosin in Prostatic Hyperplasia are open now, in 1 country. Recruiting first, the newest first:
Beni-Suef University · Sites in Egypt
Ages 50+ · Men only
Mohsen Pourazizi
Ages 50+ · Men only
Mohsen Pourazizi
Ages 50+ · Men only
Ain Shams University · Sites in Egypt
Ages 50+ · Men only
By country, each count listing its studies:
silodosin: first FDA approval 2008 (RAPAFLO), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 50 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2005.
This study's enrollment of 461 is above the median of 92 across 627 interventional studies indexed under Prostatic Hyperplasia.
Median enrollment 141 across the 19 interventional studies. Of the 15 that completed or were terminated, 4 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 19 have an industry lead sponsor. The 10 most frequent:
This study is registered under Watson Pharmaceuticals, one of the names counted as AbbVie. Under that name alone:
Watson Pharmaceuticals is the lead sponsor of 30 studies on the registry; none are open to participants now.
AbbVie has 8 studies filed under Prostatic Hyperplasia — fewer than ten, so there is no comparison to draw.
3 of the studies testing silodosin in Prostatic Hyperplasia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07743034Mohsen PouraziziIris Structural Changes With Tamsulosin vs. Silodosin in Benign Prostatic Hyperplasia Patients | 2027-04 |
| NCT07743060Mohsen PouraziziPupil Size and Choroidal Thickness Changes With Tamsulosin vs. Silodosin in Benign Prostatic Hyperplasia Patients | 2027-04 |
| NCT07650968Beni-Suef UniversityTamsulosin Dose Escalation or Silodosin Switch Before Trial Without Catheter in BPH-Related Acute Urinary Retention | 2027-05 |
Add all 3 to your calendar (.ics) → With an account.
Among the 19 studies testing silodosin in Prostatic Hyperplasia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is safe and effective. The study lasts approximately 20 weeks.
This will be a multi-center, double-blind, placebo controlled, parallel, 12 week treatment trial in men with signs and symptoms of benign prostatic hyperplasia. The following procedures are utilized: physical exams, electrocardiograms, clinical laboratory tests, vital signs, the International Prostate Symptom Score, maximum urine flow rate, pharmacokinetics, adverse events, concomitant medications, quality of life, and compliance.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Silodosin 8 mg once daily with food
Drug: Silodosin
Matching Placebo capsule once daily with food
Other: Placebo
8 mg daily for 12 weeks
Also known as: Rapaflo
1 capsule daily for 12 weeks
International Prostate Symptom Score (IPSS)
Change from baseline In IPSS at Week 12. IPSS uses a 0 to 35 scale; 0 best, 35 worse symptoms
Time frame: 12 weeks
Maximum Urine Flow Rate (Qmax)
Change from baseline in maximum urine flow rate (Qmax)at Week 12
Time frame: 12 weeks
| Milestone | Silodosin | Placebo |
|---|---|---|
| Started | 233 | 228 |
| Completed | 202 | 214 |
| Not completed | 31 | 14 |
| Withdrew: Adverse event | 20 | 6 |
| Withdrew: Protocol violation | 2 | 3 |
| Withdrew: Withdrawal by subject | 1 | 4 |
| Withdrew: Lack of efficacy | 2 | 0 |
| Withdrew: Lost to follow-up | 4 | 0 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Other | 1 | 1 |
Change from baseline In IPSS at Week 12. IPSS uses a 0 to 35 scale; 0 best, 35 worse symptoms
| Units on a 0 to 35 scale | Silodosin | Placebo |
|---|---|---|
| Baseline IPSS | 21.5 ± 5.38 | 21.4 ± 4.91 |
| Change from Baseline in IPSS at Week 12 | -6.5 ± 6.73 | -3.6 ± 5.85 |
Change from baseline in maximum urine flow rate (Qmax)at Week 12
| mL/sec | Silodosin | Placebo |
|---|---|---|
| Baseline Qmax | 9.0 ± 2.60 | 9.0 ± 2.85 |
| Change from Baseline in Qmax at Week 12 | 2.2 ± 4.31 | 1.2 ± 3.81 |
Collected over 12 weeks. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Silodosin | — | 3/233 (1.3%) | 116/233 (49.8%) |
| Placebo | — | 3/228 (1.3%) | 24/228 (10.5%) |
| Event | Silodosin | Placebo |
|---|---|---|
| Myocardial infarctionCardiac disorders | 2/233 | 1/228 |
| Cerebral haemorrhageNervous system disorders | 0/233 | 1/228 |
| DiverticulitisInfections and infestations | 0/233 | 1/228 |
| Small intestinal obstructionGastrointestinal disorders | 0/233 | 1/228 |
| Cardiac failure congestiveCardiac disorders | 1/233 | 0/228 |
| Enterococcal bacteremiaInfections and infestations | 1/233 | 0/228 |
| PneumoniaInfections and infestations | 1/233 | 0/228 |
| RadiculopathyNervous system disorders | 1/233 | 0/228 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/233 | 0/228 |
| Event | Silodosin | Placebo |
|---|---|---|
| Retrograde ejaculationReproductive system and breast disorders | 68/233 | 2/228 |
| HeadacheNervous system disorders | 8/233 | 3/228 |
| NasopharyngitisInfections and infestations | 5/233 | 7/228 |
| DiarrhoeaGastrointestinal disorders | 7/233 | 1/228 |
| DizzinessNervous system disorders | 6/233 | 4/228 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 6/233 | 0/228 |
| Orthostatic hypotensionVascular disorders | 6/233 | 5/228 |
| InsomniaNervous system disorders | 5/233 | 0/228 |
| SinusitisInfections and infestations | 5/233 | 2/228 |
| Age, Categorical(Participants) | Silodosin | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 136 | 130 | 266 |
| >=65 years | 97 | 98 | 195 |
| Age Continuous(years) | Silodosin | Placebo | Total |
|---|---|---|---|
| Mean | 64.4 ± 7.94 | 64.0 ± 7.84 | 64.2 ± 7.88 |
| Sex: Female, Male(Participants) | Silodosin | Placebo | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 233 | 228 | 461 |
| Region of Enrollment(participants) | Silodosin | Placebo | Total |
|---|---|---|---|
| United States | 233 | 228 | 461 |
The record gives a start of May 2005, a primary completion of Aug 2006 and a completion of Aug 2006. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2009, 3 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Silodosin